Bibliographic Details
| Title: |
MEDICAMENT FOR THE TREATMENT OF VIRAL SKIN AND TUMOUR DISEASES |
| Document Number: |
20110009481 |
| Publication Date: |
January 13, 2011 |
| Appl. No: |
12/887250 |
| Application Filed: |
September 21, 2010 |
| Abstract: |
The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m-O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—R3]- group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof. |
| Inventors: |
Chang, Yunik (Sonoma, CA, US); Lathrop, Robert (Fort Collins, CO, US); Böhm, Erwin (Ladenburg, DE); Gander-Meisterernst, Irene (Stockdorf, DE); Greger, Regina (Iffeldorf, DE); Holldack, Johanna (Aarhus C, DK); Moebius, Ulrich (Gauting-Unterbrunn, DE) |
| Assignees: |
MediGene AG (Planegg, DE) |
| Claim: |
1. A pharmaceutical composition comprising: (i) a compound having the formula A-B (I), wherein A is a radical having the formula [chemical expression included] and wherein B is a radical having the formula —O—R2 (III), and wherein R1 is, independent of each other, an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C13-C21 alkyl, alkylene, or alkynyl radical, and R2 is, independent of each other, an unbranched or branched C1-C8 alkyl, alkylene, or alkynyl radical; and (ii) a mixture of catechols comprising 4-15% (w/w) of (−)-epicatechol, 2-20% (w/w) of (−)-epicatechol gallate, 3-15% (w/w) of (−)-epigallocatechol, 40-75% (w/w) of (−)-epigallocatechol gallate, 0.1-1% (w/w) of (+)-gallocatechol, and 1-10% (w/w) of (−)-gallocatechol gallate; and wherein the pharmaceutical comprises at least 5-50% (w/w) of the compound of formula (I). |
| Claim: |
2. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition comprises 1-30% (w/w) of said mixture of catechols and at least 10-50% (w/w) of said compound of formula (I). |
| Claim: |
3. The pharmaceutical composition of claim 2, wherein said pharmaceutical composition comprises 2-20% (w/w) of said mixture of catechols. |
| Claim: |
4. The pharmaceutical composition of claim 3, wherein said pharmaceutical composition comprises 15-18% (w/w) of said mixture of catechols. |
| Claim: |
5. The pharmaceutical composition of claim 2, wherein said pharmaceutical composition comprises at least 25-50% (w/w) of said compound of formula (I). |
| Claim: |
6. The pharmaceutical composition of claim 5, wherein said pharmaceutical composition comprises at least 35-50% (w/w) of said compound of formula (I). |
| Claim: |
7. The pharmaceutical composition of claim 1, wherein said mixture of catechols comprises 5-7% (w/w) of said (−)-epicatechol gallate. |
| Claim: |
8. The pharmaceutical composition of claim 1, wherein said mixture of catechols comprises 0.1-0.6% (w/w) of said (+)-gallocatechol. |
| Claim: |
9. The pharmaceutical composition of claim 1, wherein said mixture of catechols comprises 1-5% (w/w) of said (−)-gallocatechol gallate. |
| Claim: |
10. The pharmaceutical composition of claim 1, wherein said mixture of catechols comprises 10.8% (w/w) of (−)-epicatechol, 6.5% (w/w) of (−)-epicatechol gallate, 9.2% (w/w) of (−)-epigallocatechol, 54.8% (w/w) of (−)-epigallocatechol gallate, and/or 4.0% (w/w) of (−)-gallocatechol gallate. |
| Claim: |
11. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition comprises at least 10-50% (w/w) of said compound of formula (I). |
| Claim: |
12. The pharmaceutical composition of claim 11, wherein said pharmaceutical composition comprises at least 25-50% (w/w) of said compound of formula (I). |
| Claim: |
13. The pharmaceutical composition of claim 12, wherein said pharmaceutical composition comprises at least 35-50% (w/w) of said compound of formula (I). |
| Claim: |
14. The pharmaceutical composition of claim 1, wherein said catechols are isolated from a tea extract. |
| Claim: |
15. The pharmaceutical composition of claim 1, wherein one or more additional pharmaceutical compound(s) is/are administered simultaneously or separately. |
| Claim: |
16. The pharmaceutical composition of claim 15, wherein said one or more additional pharmaceutical compound(s) is/are amphiphilic. |
| Claim: |
17. The pharmaceutical composition of claim 1, further comprising additives and/or auxiliary substances. |
| Claim: |
18. The pharmaceutical composition of claim 17, wherein said additives and/or auxiliary substances are hydrophobic and are selected from the group consisting of petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate, and propylene glycol monopalmitostearate. |
| Claim: |
19. A pharmaceutical composition comprising 35% (w/w) of a compound having the formula A-B (I), wherein A is a radical having the formula [chemical expression included] and wherein B is a radical having the formula —O—R2 (III), and wherein R1 is, independent of each other, an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C13-C21 alkyl, alkylene, or alkynyl radical, and R2 is, independent of each other, an unbranched or branched C1-C8 alkyl, alkylene, or alkynyl radical; and wherein said pharmaceutical composition further comprises 15% (w/w) of a mixture of catechols comprising 4-15% (w/w) of (−)-epicatechol, 2-20% (w/w) of (−)-epicatechol gallate, 3-15% (w/w) of (−)-epigallocatechol, 40-75% (w/w) of (−)-epigallocatechol gallate, 0.1-1% (w/w) of (+)-gallocatechol, 1-10% (w/w) of (−)-gallocatechol gallate, 24.5% (w/w) of petroleum jelly, 20% (w/w) of wax, 5% (w/w) of propylene glycol monostearate or propylene glycol monopalmitostearate, and 0.5% (w/w) of oleyl alcohol. |
| Claim: |
20. A method of treating a papilloma virus-induced skin disease or benign tumor disease in a patient, said method comprising administering to a patient a pharmaceutical composition of claim 1. |
| Claim: |
21. The method of claim 20, wherein said papilloma virus-induced skin disease or benign tumor disease is caused by HPV 1, 2, 3, 4, 5, 6, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19-29, 31, 32, 34, 36-38, 46-50, 56, or 58. |
| Claim: |
22. The method of claim 20, wherein said papilloma virus-induced skin diseases are warts or genital warts and the papilloma virus-induced benign tumors are of the skin and/or mucosa. |
| Claim: |
23. The method of claim 22, wherein said papilloma virus-induced benign tumors of the skin and/or mucosa are verrucae plantares, verrucae vulgares, verrucae planae juveniles, epidermodysplasia verruciformis, Condylomata acuminata, Condylomata plana, bowenoid papulosis, papillomas on the larynx and oral mucosa, or focal epithelial hyperplasia. |
| Claim: |
24. The method of claim 20, wherein said pharmaceutical composition is applied topically. |
| Claim: |
25. The method of claim 24, wherein said pharmaceutical composition is applied genitally or vaginally. |
| Current U.S. Class: |
514/456 |
| Current International Class: |
61; 61; 61 |
| Accession Number: |
edspap.20110009481 |
| Database: |
USPTO Patent Applications |
